The utility of STAT6 and ALDH1 expression in the differential diagnosis of solitary fibrous tumor versus prostate-specific stromal neoplasms

Gunes Guner, Justin A. Bishop, Stephania M. Bezerra, Diana Taheri, David J. Zahavi, Maria Angelica Mendoza Rodriguez, Rajni Sharma, Jonathan Ira Epstein, George J. Netto

Research output: Contribution to journalArticle

Abstract

Solitary fibrous tumor (SFT) diagnosis in prostate can be challenging on small biopsies. Prostatic stromal tumors of unknown malignant potential (STUMP) and SFT have overlapping features. NAB2-STAT6 gene fusions that were recently identified in various SFTs lead to nuclear translocalization of STAT6. Nuclear STAT6 immunostaining is now considered an adjunct for SFT diagnosis. We evaluated STAT6 and an emerging stemness marker, ALDH1, in the differential diagnosis of SFT versus prostatic stromal lesions. Sixteen STUMPs, 12 SFTs, and 4 prostatic stromal sarcomas (12 needle biopsies, 13 radical prostatectomies, 7 transurethral resections) were retrieved (1995-2015). Sections were stained with polyclonal STAT6 antibody (Santa Cruz Biotechnology, Santa Cruz, CA; S20, 1:100) and monoclonal ALDH1 antibody (BD Biosciences, San Jose, CA; clone 44, 1:250). In STAT6 cases, only unequivocal nuclear staining (with/without cytoplasmic staining) was considered positive. Cytoplasmic ALDH1 staining was counted positive. Ten of 11 evaluable SFTs demonstrated strong and diffuse nuclear STAT6 positivity; 4 of 16 STUMPs had nuclear staining that was weak (1/4) or focal (1/4). ALDH1 positivity was seen in 10 of 12 evaluable SFTs and 3 of 15 STUMPs. Prostatic stromal sarcomas were STAT6 negative (4/4); 2 of 4 were ALDH1 positive. The sensitivity and specificity for STAT6 for the diagnosis of SFT were 91% and 75%, respectively. Coexpression of STAT6 and ALDH1 yielded the same sensitivity but improved the specificity (100%) for the diagnosis of SFT. STAT6 is a useful marker in the differential diagnosis of SFT versus STUMP. Using STAT6 and ALDH1 together increases specificity. STUMPs can show STAT6 positivity, and when they do, it is likely to be weak or focal.

Original languageEnglish (US)
Pages (from-to)184-188
Number of pages5
JournalHuman Pathology
Volume54
DOIs
StatePublished - Aug 1 2016

Fingerprint

Solitary Fibrous Tumors
Prostate
Differential Diagnosis
Neoplasms
Staining and Labeling
Sarcoma
Sensitivity and Specificity
Transurethral Resection of Prostate
Gene Fusion
Needle Biopsy
Biotechnology
aldehyde dehydrogenase 1
Clone Cells
Monoclonal Antibodies
Biopsy
Antibodies

Keywords

  • ALDH1
  • Immunohistochemistry
  • Prostate
  • SFT
  • STAT6
  • Stromal
  • STUMP

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Guner, G., Bishop, J. A., Bezerra, S. M., Taheri, D., Zahavi, D. J., Mendoza Rodriguez, M. A., ... Netto, G. J. (2016). The utility of STAT6 and ALDH1 expression in the differential diagnosis of solitary fibrous tumor versus prostate-specific stromal neoplasms. Human Pathology, 54, 184-188. https://doi.org/10.1016/j.humpath.2016.03.011

The utility of STAT6 and ALDH1 expression in the differential diagnosis of solitary fibrous tumor versus prostate-specific stromal neoplasms. / Guner, Gunes; Bishop, Justin A.; Bezerra, Stephania M.; Taheri, Diana; Zahavi, David J.; Mendoza Rodriguez, Maria Angelica; Sharma, Rajni; Epstein, Jonathan Ira; Netto, George J.

In: Human Pathology, Vol. 54, 01.08.2016, p. 184-188.

Research output: Contribution to journalArticle

Guner, Gunes ; Bishop, Justin A. ; Bezerra, Stephania M. ; Taheri, Diana ; Zahavi, David J. ; Mendoza Rodriguez, Maria Angelica ; Sharma, Rajni ; Epstein, Jonathan Ira ; Netto, George J. / The utility of STAT6 and ALDH1 expression in the differential diagnosis of solitary fibrous tumor versus prostate-specific stromal neoplasms. In: Human Pathology. 2016 ; Vol. 54. pp. 184-188.
@article{8e940eb3c7a3475e9b971fd65c6a7f96,
title = "The utility of STAT6 and ALDH1 expression in the differential diagnosis of solitary fibrous tumor versus prostate-specific stromal neoplasms",
abstract = "Solitary fibrous tumor (SFT) diagnosis in prostate can be challenging on small biopsies. Prostatic stromal tumors of unknown malignant potential (STUMP) and SFT have overlapping features. NAB2-STAT6 gene fusions that were recently identified in various SFTs lead to nuclear translocalization of STAT6. Nuclear STAT6 immunostaining is now considered an adjunct for SFT diagnosis. We evaluated STAT6 and an emerging stemness marker, ALDH1, in the differential diagnosis of SFT versus prostatic stromal lesions. Sixteen STUMPs, 12 SFTs, and 4 prostatic stromal sarcomas (12 needle biopsies, 13 radical prostatectomies, 7 transurethral resections) were retrieved (1995-2015). Sections were stained with polyclonal STAT6 antibody (Santa Cruz Biotechnology, Santa Cruz, CA; S20, 1:100) and monoclonal ALDH1 antibody (BD Biosciences, San Jose, CA; clone 44, 1:250). In STAT6 cases, only unequivocal nuclear staining (with/without cytoplasmic staining) was considered positive. Cytoplasmic ALDH1 staining was counted positive. Ten of 11 evaluable SFTs demonstrated strong and diffuse nuclear STAT6 positivity; 4 of 16 STUMPs had nuclear staining that was weak (1/4) or focal (1/4). ALDH1 positivity was seen in 10 of 12 evaluable SFTs and 3 of 15 STUMPs. Prostatic stromal sarcomas were STAT6 negative (4/4); 2 of 4 were ALDH1 positive. The sensitivity and specificity for STAT6 for the diagnosis of SFT were 91{\%} and 75{\%}, respectively. Coexpression of STAT6 and ALDH1 yielded the same sensitivity but improved the specificity (100{\%}) for the diagnosis of SFT. STAT6 is a useful marker in the differential diagnosis of SFT versus STUMP. Using STAT6 and ALDH1 together increases specificity. STUMPs can show STAT6 positivity, and when they do, it is likely to be weak or focal.",
keywords = "ALDH1, Immunohistochemistry, Prostate, SFT, STAT6, Stromal, STUMP",
author = "Gunes Guner and Bishop, {Justin A.} and Bezerra, {Stephania M.} and Diana Taheri and Zahavi, {David J.} and {Mendoza Rodriguez}, {Maria Angelica} and Rajni Sharma and Epstein, {Jonathan Ira} and Netto, {George J.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.humpath.2016.03.011",
language = "English (US)",
volume = "54",
pages = "184--188",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - The utility of STAT6 and ALDH1 expression in the differential diagnosis of solitary fibrous tumor versus prostate-specific stromal neoplasms

AU - Guner, Gunes

AU - Bishop, Justin A.

AU - Bezerra, Stephania M.

AU - Taheri, Diana

AU - Zahavi, David J.

AU - Mendoza Rodriguez, Maria Angelica

AU - Sharma, Rajni

AU - Epstein, Jonathan Ira

AU - Netto, George J.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Solitary fibrous tumor (SFT) diagnosis in prostate can be challenging on small biopsies. Prostatic stromal tumors of unknown malignant potential (STUMP) and SFT have overlapping features. NAB2-STAT6 gene fusions that were recently identified in various SFTs lead to nuclear translocalization of STAT6. Nuclear STAT6 immunostaining is now considered an adjunct for SFT diagnosis. We evaluated STAT6 and an emerging stemness marker, ALDH1, in the differential diagnosis of SFT versus prostatic stromal lesions. Sixteen STUMPs, 12 SFTs, and 4 prostatic stromal sarcomas (12 needle biopsies, 13 radical prostatectomies, 7 transurethral resections) were retrieved (1995-2015). Sections were stained with polyclonal STAT6 antibody (Santa Cruz Biotechnology, Santa Cruz, CA; S20, 1:100) and monoclonal ALDH1 antibody (BD Biosciences, San Jose, CA; clone 44, 1:250). In STAT6 cases, only unequivocal nuclear staining (with/without cytoplasmic staining) was considered positive. Cytoplasmic ALDH1 staining was counted positive. Ten of 11 evaluable SFTs demonstrated strong and diffuse nuclear STAT6 positivity; 4 of 16 STUMPs had nuclear staining that was weak (1/4) or focal (1/4). ALDH1 positivity was seen in 10 of 12 evaluable SFTs and 3 of 15 STUMPs. Prostatic stromal sarcomas were STAT6 negative (4/4); 2 of 4 were ALDH1 positive. The sensitivity and specificity for STAT6 for the diagnosis of SFT were 91% and 75%, respectively. Coexpression of STAT6 and ALDH1 yielded the same sensitivity but improved the specificity (100%) for the diagnosis of SFT. STAT6 is a useful marker in the differential diagnosis of SFT versus STUMP. Using STAT6 and ALDH1 together increases specificity. STUMPs can show STAT6 positivity, and when they do, it is likely to be weak or focal.

AB - Solitary fibrous tumor (SFT) diagnosis in prostate can be challenging on small biopsies. Prostatic stromal tumors of unknown malignant potential (STUMP) and SFT have overlapping features. NAB2-STAT6 gene fusions that were recently identified in various SFTs lead to nuclear translocalization of STAT6. Nuclear STAT6 immunostaining is now considered an adjunct for SFT diagnosis. We evaluated STAT6 and an emerging stemness marker, ALDH1, in the differential diagnosis of SFT versus prostatic stromal lesions. Sixteen STUMPs, 12 SFTs, and 4 prostatic stromal sarcomas (12 needle biopsies, 13 radical prostatectomies, 7 transurethral resections) were retrieved (1995-2015). Sections were stained with polyclonal STAT6 antibody (Santa Cruz Biotechnology, Santa Cruz, CA; S20, 1:100) and monoclonal ALDH1 antibody (BD Biosciences, San Jose, CA; clone 44, 1:250). In STAT6 cases, only unequivocal nuclear staining (with/without cytoplasmic staining) was considered positive. Cytoplasmic ALDH1 staining was counted positive. Ten of 11 evaluable SFTs demonstrated strong and diffuse nuclear STAT6 positivity; 4 of 16 STUMPs had nuclear staining that was weak (1/4) or focal (1/4). ALDH1 positivity was seen in 10 of 12 evaluable SFTs and 3 of 15 STUMPs. Prostatic stromal sarcomas were STAT6 negative (4/4); 2 of 4 were ALDH1 positive. The sensitivity and specificity for STAT6 for the diagnosis of SFT were 91% and 75%, respectively. Coexpression of STAT6 and ALDH1 yielded the same sensitivity but improved the specificity (100%) for the diagnosis of SFT. STAT6 is a useful marker in the differential diagnosis of SFT versus STUMP. Using STAT6 and ALDH1 together increases specificity. STUMPs can show STAT6 positivity, and when they do, it is likely to be weak or focal.

KW - ALDH1

KW - Immunohistochemistry

KW - Prostate

KW - SFT

KW - STAT6

KW - Stromal

KW - STUMP

UR - http://www.scopus.com/inward/record.url?scp=84971524723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971524723&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2016.03.011

DO - 10.1016/j.humpath.2016.03.011

M3 - Article

VL - 54

SP - 184

EP - 188

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -